Efficacy of salvage chemotherapy in diffuse large B cell lymphoma with primary treatment failure according to putative cell of origin.


:We evaluated outcome of 235 primary treatment failure (PTF) diffuse large B-cell lymphoma (DLBCL) patients based on salvage chemotherapy regimen and putative cell-of-origin (COO). Patients were divided into two groups; group A (n = 38) received high-dose cytarabine containing regimen, either DHAP or ESHAP. Patients in group B (n = 197) received ifosfamide, carboplatin, and etoposide (ICE) +/- rituximab. No difference in overall response rates (CR + PR) was observed based on salvage chemotherapy regimen and COO. After adjustment for the presence of ultra high-risk features, overall survival of germinal center B-cell like (GCB) DLBCL patients in group A was not significantly different from survival in group B (HR 0.86, 95% CI 0.46-1.60, p = .64). Similarly, within non-GCB DLBCL cohort, survival in group A was comparable to group B (HR 0.53, 95% CI 0.20-1.44, p = .21). We did not find an outcome difference between two commonly used salvage chemotherapy regimens in patients with PTF DLBCL based on COO.


Leuk Lymphoma


Leukemia & lymphoma


Badar T,Hamadani M,Bachanova V,Maddocks KJ,Umyarova E,Chavez JC,Epperla N,Chhabra S,Xavier AC,Karmali R,Salhab M,Reddy N,Glenn MJ,Hernandez-Ilizaliturri FJ,Flowers CR,Evens AM,Zhou Z,Lansigan F,Barta SK,Cohen JB,F




Has Abstract


2019-04-01 00:00:00












  • Interferon-alpha combined with cytarabine in chronic myelogenous leukemia - clinical benefits.

    abstract::During the last decade, several studies have evaluated the treatment of chronic phase chronic myeloid leukemia (CML) with a combination of interferon (IFN)-alpha and low- dose cytarabine (Ara-C). This combination therapy has been shown to be superior compared to monotherapy with IFN-alpha in randomized studies with re...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审


    authors: Lindauer M,Fischer T

    更新日期:2001-05-01 00:00:00

  • Non-surgical treatment with primary chemotherapy, with or without radiation therapy, of stage I-II high-grade gastric lymphoma.

    abstract::Morbidity, mortality and discomfort related to gastrectomy has led some investigators to treat patients with stage I-II primary gastric high-grade lymphoma (PGL) with a conservative strategy. Here we report a retrospective series of 21 patients with PGL treated with primary chemotherapy alone or followed by radiation ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章


    authors: Ferreri AJ,Cordio S,Ponzoni M,Villa E

    更新日期:1999-05-01 00:00:00

  • Isolated myelosarcoma in children--update and review.

    abstract::Primary myelosarcomas, also called leukemia cutis, granulocytic sarcomas or chloromas, are rare extramedullary manifestations of acute myeloid leukemia (AML) which precede bone marrow involvement. Skin infiltration was the most frequent localization associated with a myelomonocytic differentiation. Although first remi...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审


    authors: Reinhardt D,Creutzig U

    更新日期:2002-03-01 00:00:00

  • A phase II study of bortezomib and gemcitabine in relapsed mantle cell lymphoma from the National Cancer Institute of Canada Clinical Trials Group (IND 172).

    abstract::Bortezomib and gemcitabine have each shown activity as single agents in mantle cell lymphoma (MCL), which is incurable. The purpose of this phase II study was to determine the efficacy and safety of the previously unstudied combination of bortezomib and gemcitabine in patients with relapsed or refractory MCL. Patients...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,多中心研究


    authors: Kouroukis CT,Fernandez LA,Crump M,Gascoyne RD,Chua NS,Buckstein R,Turner R,Assouline S,Klasa RJ,Walsh W,Powers J,Eisenhauer E

    更新日期:2011-03-01 00:00:00

  • Treatment of Waldenstrom's macroglobulinemia with rituximab: prognostic factors for response and progression.

    abstract::Recent data have suggested that rituximab is an active agent for the treatment of Waldenstrom's macroglobulinemia (WM). However, the patients that are more likely to benefit have not been clearly defined. In order to address this question we evaluated 52 patients who were treated with single-agent rituximab in the con...

    journal_title:Leukemia & lymphoma

    pub_type: 临床试验,杂志文章


    authors: Dimopoulos MA,Alexanian R,Gika D,Anagnostopoulos A,Zervas C,Zomas A,Kyrtsonis MC,Anagnostopoulos N,Pangalis GA,Weber DM

    更新日期:2004-10-01 00:00:00

  • Primary hematolymphoid malignancies involving the extrahepatic bile duct or gallbladder.

    abstract::Primary hematolymphoid malignancies of the extrahepatic biliary tract are rare tumors. We report five cases of primary hematolymphoid malignancies involving the extrahepatic biliary tract. One is a granulocytic sarcoma of the extrahepatic bile duct, another is an extramedullary plasmacytoma of the gallbladder, and the...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章


    authors: Hwang DW,Lim CS,Jang JY,Lee SE,Yoon SO,Jeon YK,Uk Lee K,Kim SW

    更新日期:2010-07-01 00:00:00

  • Tocilizumab, in search for a role in acute GVHD.

    abstract::Acute graft versus host disease (aGVHD) was first described by Barnes et al. in 1962, who reported a 'secondary disease' in mice after irradiation and infusion of allogeneic spleen cells. The disease manifested as fatal diarrhea and skin abnormalities. They postulated that aGVHD resulted from introducing immunological...

    journal_title:Leukemia & lymphoma

    pub_type: 评论,杂志文章


    authors: Gergis U,van Besien K

    更新日期:2019-09-01 00:00:00

  • Single agent lenalidomide in newly diagnosed multiple myeloma: a retrospective analysis.

    abstract::Recently, lenalidomide and low dose dexamethasone were found to result in superior overall survival compared to lenalidomide and high dose dexamethasone. The immune suppressive effects of dexamethasone can antagonize lenalidomide immunomodulatory activity and may explain this observation. We conducted a retrospective ...

    journal_title:Leukemia & lymphoma

    pub_type: 临床试验,杂志文章,多中心研究


    authors: Baz R,Patel M,Finley-Oliver E,Lebovic D,Hussein MA,Miller KC,Wood M,Sher T,Lee K,Chanan-Khan AA

    更新日期:2010-06-01 00:00:00

  • c-mpl expression in hematologic disorders.

    abstract::The c-mpl gene encodes a member of the hematopoietic cytokine receptor superfamily. This gene was discovered through the study of a murine retrovirus which induces an acute myeloproliferative syndrome in mice. MPLV (for myeloproliferative leukemia virus) has transduced a truncated and constitutively activated form of ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审


    authors: Bouscary D,Prudhomme C,Quesnel B,Melle J,Picard F,Dreyfus F

    更新日期:1995-03-01 00:00:00

  • Primary multifocal lymphoma of bone presenting as hypercalcemic crisis: report of a rare manifestation of extranodal lymphoma.

    abstract::Primary non-Hodgkin's lymphoma of bone is uncommon and usually manifests clinically as localized bone pain. Here we report a woman who presented with hypercalcemic crisis and extensive investigation revealed a primary multifocal lymphoma of bone. The course of the disease was very aggressive and despite intensive supp...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章


    authors: Evron E,Goland S,Klepfish A,Malnick SD,Sokolowski N,Sthoeger ZM

    更新日期:1999-06-01 00:00:00

  • Invasive fungal sinusitis: an effective combined treatment in five haematological patients.

    abstract::Invasive fungal rhinosinusitis (IFR) is a life-threatening infection. Its onset is subtle and a late diagnosis leads to severe complications. Death may occur within a few weeks notwithstanding treatment. We describe a comprehensive pre- and post-operative approach to care for haematological patients with IFR. Five hae...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章


    authors: Vener C,Carrabba M,Fracchiolla NS,Costa A,Fabio G,Hu C,Sina C,Guastella C,Pignataro L,Deliliers GL

    更新日期:2007-08-01 00:00:00

  • The role of T cell costimulation by CD80 in the initiation and maintenance of the immune response to human leukemia.

    abstract::Most human myeloid leukemias express both class I and class II HLA and it has been postulated that leukemia-associated peptides are presented by those molecules. It is possible, however, that leukemia cells escape the immune surveillance by lacking expression of "costimulatory" molecules required for activating the im...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章


    authors: Matsumoto K,Anasetti C

    更新日期:1999-11-01 00:00:00

  • Lack of CD54 expression and mutation of p53 gene relate to the prognosis of childhood Burkitt's lymphoma.

    abstract::Expression of the intercellular adhesion molecule-1 (CD54) as well as the mutations of p53 gene were studied in childhood Burkitt's lymphoma (BL). Expression of CD54 was identified in 6 of 15 fresh BL cases. Mutations of p53 gene, analyzed by polymerase chain reaction-single stranded chain polymorphism followed by seq...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章


    authors: Kaneko H,Sugita K,Kiyokawa N,Iizuka K,Takada K,Saito M,Yoshimoto K,Itakura M,Kokai Y,Fujimoto J

    更新日期:1996-05-01 00:00:00

  • Interdigitating dendritic cell sarcoma: a rare malignancy responsive to ABVD chemotherapy.

    abstract::Interdigitating dendritic cell sarcoma (IDCS) is an aggressive neoplasm of which fewer than 25 cases have been reported in the world literature. This malignancy is difficult to diagnose because of its rarity, and because of the subtle histopathologic features that distinguish IDCS from similar tumors arising from reti...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章


    authors: Olnes MJ,Nicol T,Duncan M,Bohlman M,Erlich R

    更新日期:2002-04-01 00:00:00

  • The anti-leukemic and lipid lowering effects of imatinib are not hindered by statins in CML: a retrospective clinical study and in vitro assessment of lipid-genes transcription.

    abstract::Imatinib, which has revolutionized chronic myeloid leukemia (CML) treatment, was suggested to improve lipid profile. Statins, a dyslipidemia drug, were reported to potentiate imatinib's antileukemic effect. However, analysis of imatinib combined with statins is lacking. We have retrospectively analyzed the normalizati...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章


    authors: Ellis M,Krashin E,Hamburger-Avnery O,Gan S,Elis A,Ashur-Fabian O

    更新日期:2017-05-01 00:00:00

  • Statins induce lethal effects in acute myeloblastic leukemia [corrected] cells within 72 hours.

    abstract::HMG-CoA Reductase inhibitors (statins) induce apoptosis in acute myeloid leukemia (AML) cells in vitro; however, the concentrations associated with cell death in AML cells are higher than those clinically tolerated during prolonged therapy. We therefore wished to determine whether short exposures to lovastatin might i...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章


    authors: Burke LP,Kukoly CA

    更新日期:2008-02-01 00:00:00

  • MACOP-B vs F-MACHOP regimen in the treatment of high-grade non-Hodgkin's lymphomas.

    abstract::A prospective randomized study on aggressive non-Hodgkin's lymphomas was conducted by investigators at several Italian institutions with the intent of comparing two third-generation conceptually different regimens: the regimen containing methotrexate with leucovorin rescue, doxorubicin, cyclophosphamide, vincristine, ...

    journal_title:Leukemia & lymphoma

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验


    authors: Mazza P,Zinzani PL,Martelli M,Fiacchini M,Bocchia M,Pileri S,Falini B,Martelli MF,Amadori S,Papa G

    更新日期:1995-02-01 00:00:00

  • Double isochromosome 8q as single cytogenetic aberration in acute myelo-monocytic leukemia.

    abstract::We report a case of double isochromosome 8q as a single cytogenetic abnormality in a patient with acute myelo-monocytic leukemia. Similarly to rare cases with tetrasomy 8, the patient showed monocytic involvement and was refractory to cytotoxic chemotherapy. We conclude that this kind of cytogenetic aberration is prob...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章


    authors: Vicari L,Sebastio L,Cirigliano V,Pugliese MT,Ferrara F

    更新日期:1995-10-01 00:00:00

  • Blast crisis of Ph-positive chronic myeloid leukemia with isochromosome 17q: report of 12 cases and review of the literature.

    abstract::Isochromosome 17q [i(17q)] is frequently observed in the blast crisis (BC) of chronic myelogenous leukemia (CML). It has been suggested that this chromosome abnormality is associated with special hematological characteristics of the BC, but the information on this subject is scarce. The clinical, hematological and cyt...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章


    authors: Hernández-Boluda JC,Cervantes F,Costa D,Carrió A,Montserrat E

    更新日期:2000-06-01 00:00:00

  • Ruxolitinib is effective in patients with intermediate-1 risk myelofibrosis: a summary of recent evidence.

    abstract::Ruxolitinib is the only therapy with an approved indication for myelofibrosis (MF), a myeloproliferative neoplasm associated with progressive bone marrow fibrosis and extramedullary hematopoiesis. Although the pivotal phase 3 COMFORT studies included only patients with intermediate-2 or high-risk MF, the US indication...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审


    authors: Harrison CN,Talpaz M,Mead AJ

    更新日期:2016-10-01 00:00:00

  • Therapy for Philadelphia chromosome-positive acute lymphoblastic leukemia: possible use of interferon on the basis of some novel concepts.

    abstract::Current understanding of molecular genetics enables the establishment of new categories based on pathogenesis. Philadelphia (Ph) chromosome-positive leukemia has been reclassified into two molecularly distinct subsets, and the leukemogenesis at the cell level might be linked to the molecular changes. Therefore, treatm...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审


    authors: Ohyashiki K,Ohyashiki JH,Toyama K

    更新日期:1993-01-01 00:00:00

  • CD25 expression and outcomes in older patients with acute myelogenous leukemia treated with plerixafor and decitabine.

    abstract::We investigated CD25 expression in older (≥60 years) patients with new acute myelogenous leukemia treated with decitabine and plerixafor. Patients resistant to therapy or survival ≤1 year had significantly higher percentages of CD25pos myeloid blasts in baseline bone marrow. CD25pos patients had an increased odds of r...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章


    authors: Allan JN,Roboz GJ,Askin G,Ritchie E,Scandura J,Christos P,Hassane DC,Guzman ML

    更新日期:2018-04-01 00:00:00

  • Extensive analysis of the T315I substitution and detection of additional ABL mutations in progenitors and primitive stem cell compartment in a patient with tyrosine kinase inhibitor-resistant chronic myeloid leukemia.

    abstract::Tyrosine kinase inhibitors (TKIs) have revolutionized the treatment of chronic myeloid leukemia (CML). However, resistance is occasionally observed, mainly due to mutations within the BCR-ABL kinase domain. The T315I substitution confers complete resistance to all TKIs commonly used in clinical practice. To date, the ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章


    authors: Chomel JC,Sorel N,Bonnet ML,Bertrand A,Brizard F,Roy L,Guilhot F,Turhan AG

    更新日期:2010-11-01 00:00:00

  • Idiopathic primary osteo-myelofibrosis: a clinico-pathological study on 208 patients with special emphasis on evolution of disease features, differentiation from essential thrombocythemia and variables of prognostic impact.

    abstract::A retrospective clinico-pathological study was performed on 208 consecutively recruited patients (94 males, 114 females, median age 67 years) with idiopathic (primary) osteo-/ myelofibrosis (IMF). According to bone marrow histology (cellularity) as well as extent (semiquantitative grading) and quality (reticulin/colla...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章


    authors: Thiele J,Kvasnicka HM,Werden C,Zankovich R,Diehl V,Fischer R

    更新日期:1996-07-01 00:00:00

  • NPM-RAR binding to TRADD selectively inhibits caspase activation, while allowing activation of NFκB and JNK.

    abstract::The t(5;17) variant of acute promeylocytic leukemia (APL) expresses a fusion of nucleophosmin (NPM) with the retinoic acid receptor alpha (RARA). We have previously shown that NPM-RAR is a binding partner of the tumor necrosis factor (TNF) receptor type-I-associated DEATH domain protein, TRADD. Binding of TNF to its r...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章


    authors: Chattopadhyay A,Abecassis I,Redner RL

    更新日期:2015-01-01 00:00:00

  • Refractoriness to rituximab-based therapy and elevated serum B2-microglobulin predict for inferior survival in marginal zone lymphoma.

    abstract::Short responses to immunochemotherapy predict for an inferior OS in follicular lymphoma. We set out to determine whether this is also the case in marginal zone lymphoma. A group of 139 marginal zone lymphoma (MZL) patients treated with front-line immuno- or immunochemotherapy (I/ICT) were categorized into I/ICT-refrac...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章


    authors: Sorigue M,Bishton M,Domingo-Domenech E,McMillan A,Prusila R,García O,Kuusisto M,Condom M,Tapia G,Ribera JM,Kuittinen O,Fox CP,Sancho JM

    更新日期:2019-10-01 00:00:00

  • Prognostic impact of melphalan dose and total body irradiation use in patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation with reduced-intensity conditioning.

    abstract::To evaluate the prognostic impact of melphalan dose and total body irradiation (TBI) use in acute myeloid leukemia patients undergoing reduced-intensity allogeneic transplantation, we retrospectively compared outcomes of patients receiving a higher-dose (120-140 mg/m2, n = 379) or lower-dose melphalan (80-110 mg/m2, n...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章


    authors: Harada K,Yanada M,Machida S,Kanamori H,Onizuka M,Ozawa Y,Kobayashi H,Sawa M,Katayama Y,Ohashi K,Kanda J,Ichinohe T,Atsuta Y,Yano S

    更新日期:2019-06-01 00:00:00

  • Newer approaches in treating chronic myelogenous leukemia.

    abstract::We evaluated the recovery of human hematopoietic progenitors in long-term bone marrow culture (LTBMC) initiated in tissue culture (TC) flasks to that in "Lifecell" bags, which are gas-permeable plastic bags in which feeder-layer cells cannot adhere. Cells were incubated in presence of IL-1 and IL-3. Our experiments re...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章


    authors: Gulati SC,Lemoli R,Van Poznak C

    更新日期:1993-01-01 00:00:00

  • Primary Non-Hodgkin's Lymphomas of the Nasal and Mouth Cavity and the Waldeyer's Ring: A morphological and immunohistochemical study.

    abstract::Twenty-six non-Hodgkin's malignant lymphomas (ML) of the Waldeyer's ring, the mouth and nasal cavities were studied morphologically and immunohistochemically on paraffin and frozen sections. A B-cell origin was shown in all 14 cases of Waldeyer's ring M.L., while 5 of 7 nasal and 3 of 5 buccal cases were of T-cell nat...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章


    authors: Papadimitriou CS,Bai MK

    更新日期:1991-01-01 00:00:00

  • Regression of a plasmablastic lymphoma in a patient with HIV on highly active antiretroviral therapy.

    abstract::We describe an HIV-infected 44-year-old man who presented 1 month after discontinuation of HAART therapy with a large mass extending from the mediastinum, enclosing the heart and extending through the diaphragm to the epigastric region. Biopsies subsequently revealed a highly aggressive non-Hodgkin's lymphoma (NHL) pr...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章


    authors: Nasta SD,Carrum GM,Shahab I,Hanania NA,Udden MM

    更新日期:2002-02-01 00:00:00